StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Welireg (belzutifan by Quarter

Welireg (belzutifan — HIF-2α inhibitor) — International sales ($M) ($M)

QuarterlyAnnual

Merck Welireg (belzutifan: $57M in Q2 2026, up 137.5% from a year earlier. That is the highest of the 18 quarters on record here.

Latest, Q2 2026
57
Period ended Jun 30, 2026
Change on a year earlier
+137.5%
24 in Q2 2025
History
18 quarters
Since Q1 2022
Sources
14
Documents cited below

Where the Q2 2026 figure comes from

“|| Welireg | 271 | 162 | 67 | 214 | 138 | 55 | 57 | 24 | 133”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedWelireg (belzutifan — HIF-2α inhibitor) — International sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202657+137.5%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202647+213.3%Form 10-Q (filed 2026-05-04) ↗
Q4 2025Dec 31, 202539+178.6%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202535+191.7%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 202524+140.0%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 202515+114.3%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 202414+250.0%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 202412+300.0%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 202410+400.0%Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2024Mar 31, 20247+600.0%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 20234–Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 20233–Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 20232–Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2023Mar 31, 20231–Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2022Dec 31, 20220–Form 10-K (filed 2025-02-25) ↗
Q3 2022Sep 30, 20220–Form 10-Q (filed 2023-11-03) ↗

Cite this data

StockData. (2026). Merck Welireg (belzutifan ($M), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-welireg-intl

See every metric in the Merck KPI table. Data updated Oct 26, 2026.